Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients
- PMID: 26905317
- DOI: 10.1097/MNM.0000000000000486
Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients
Abstract
Aim: This study aimed to compare the overall survival (OS) times, long-term complications, and recurrence rates of chemoembolization and radioembolization for Barcelona Clinic Liver Cancer (BCLC) stage B-C hepatocellular cancer patients.
Materials and methods: This retrospective study included 80 BCLC stage B-C hepatocellular cancer patients who received chemoembolization (group 1) or radioembolization (group 2). The OS times, long-term complications, and disease recurrence rates of the two groups were compared. The prognostic role of sex, age, presence of underlying chronic liver disease, BCLC stage, dimension and number of liver lesions, tumor load, and presence of extrahepatic disease were also analyzed for each group.
Results: Each group included 40 (67 men, 13 women, mean age: 41.9±21.9 years) patients. During the follow-up period, 22 patients died in group 2 and 30 patients died in group 1. The overall mean survival of the entire patient group was calculated to be 37.31±3.94 months [95% confidence interval (CI), 30.46-44.1 months], with 30.63±3.68 months (95% CI, 23.42-37.84 months) for group 1 and 39.24±4.62 months (95% CI, 30.18-48.29 months) for group 2 (P=0.014). The 1- and 2-year survival rates were 72 versus 74% and 47 versus 59% for groups 2 and 1, respectively. There was no significant difference between the chronic complication (P=0.32) and disease recurrence (P=0.65) rates of the groups. Whereas the dimension of the largest lesion was the most significant predictor (P=0.01) in group 2, female sex (P=0.008), dimension of the largest lesion (P=0.03), and BCLC stage (P=0.01) were significant in group 1.
Conclusion: Although chemoembolization and radioembolization for BCLC Stage B-C patients have similar levels of safety and efficacy, they differ in OS. In this retrospective study, patients undergoing radioembolization had a longer survival rate.
Similar articles
-
Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.J Vasc Interv Radiol. 2016 Dec;27(12):1829-1836. doi: 10.1016/j.jvir.2016.06.010. Epub 2016 Aug 21. J Vasc Interv Radiol. 2016. PMID: 27553917
-
Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.J Vasc Interv Radiol. 2014 Jul;25(7):1075-84. doi: 10.1016/j.jvir.2014.04.014. Epub 2014 May 24. J Vasc Interv Radiol. 2014. PMID: 24861664 Review.
-
Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.Acad Radiol. 2018 Apr;25(4):423-429. doi: 10.1016/j.acra.2017.10.018. Epub 2017 Nov 29. Acad Radiol. 2018. PMID: 29198946
-
Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis .Int J Clin Pharmacol Ther. 2017 Jun;55(6):498-508. doi: 10.5414/CP202787. Int J Clin Pharmacol Ther. 2017. PMID: 28157070
-
Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.Drug Des Devel Ther. 2015 Aug 10;9:4431-40. doi: 10.2147/DDDT.S86629. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26309396 Free PMC article. Review.
Cited by
-
Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma.Semin Intervent Radiol. 2024 Mar 14;41(1):48-55. doi: 10.1055/s-0044-1779714. eCollection 2024 Feb. Semin Intervent Radiol. 2024. PMID: 38495267 Review.
-
Indian College of Radiology and Imaging Guidelines on Interventions in Hepatocellular Carcinoma.Indian J Radiol Imaging. 2022 Sep 19;32(4):540-554. doi: 10.1055/s-0042-1754361. eCollection 2022 Dec. Indian J Radiol Imaging. 2022. PMID: 36451961 Free PMC article. Review.
-
Transcatheter embolization of hepatocellular carcinoma with epirubicin-loaded DC beads in Chinese patients.Transl Cancer Res. 2019 Feb;8(1):279-289. doi: 10.21037/tcr.2019.01.36. Transl Cancer Res. 2019. PMID: 35116757 Free PMC article.
-
Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV.Infect Dis Rep. 2022 Jan 7;14(1):43-55. doi: 10.3390/idr14010006. Infect Dis Rep. 2022. PMID: 35076514 Free PMC article. Review.
-
Peritumoral portal enhancement during transarterial chemoembolization: a potential prognostic factor for patients with hepatocellular carcinoma.Acta Radiol. 2022 Oct;63(10):1323-1331. doi: 10.1177/02841851211041832. Epub 2021 Oct 19. Acta Radiol. 2022. PMID: 34665054 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical